Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sutro Biopharma stock

Own Sutro Biopharma stock in just a few minutes.

Sutro Biopharma, Inc is a biotechnology business based in the US. Sutro Biopharma shares (STRO) are listed on the NASDAQ and all prices are listed in US Dollars. Sutro Biopharma employs 191 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Sutro Biopharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – STRO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Sutro Biopharma share price

Use our graph to track the performance of STRO stocks over time.

Sutro Biopharma shares at a glance

Information last updated 2021-04-23.
52-week range$7.06 - $28.30
50-day moving average $21.83
200-day moving average $20.27
Wall St. target price$31.83
PE ratio 56.5986
Dividend yield N/A (0%)
Earnings per share (TTM) $0.44

Buy Sutro Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sutro Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Sutro Biopharma under- or over-valued?

Valuing Sutro Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sutro Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sutro Biopharma's P/E ratio

Sutro Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 57x. In other words, Sutro Biopharma shares trade at around 57x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Sutro Biopharma financials

Revenue TTM $42.7 million
Gross profit TTM $-34,239,000
Return on assets TTM -16.15%
Return on equity TTM -14.95%
Profit margin -75.2%
Book value $7.26
Market capitalisation $913.1 million

TTM: trailing 12 months

Shorting Sutro Biopharma shares

There are currently 3.5 million Sutro Biopharma shares held short by investors – that's known as Sutro Biopharma's "short interest". This figure is 138.6% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Sutro Biopharma shares can be evaluated.

Sutro Biopharma's "short interest ratio" (SIR)

Sutro Biopharma's "short interest ratio" (SIR) is the quantity of Sutro Biopharma shares currently shorted divided by the average quantity of Sutro Biopharma shares traded daily (recently around 708212.8). Sutro Biopharma's SIR currently stands at 5. In other words for every 100,000 Sutro Biopharma shares traded daily on the market, roughly 5000 shares are currently held short.

However Sutro Biopharma's short interest can also be evaluated against the total number of Sutro Biopharma shares, or, against the total number of tradable Sutro Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sutro Biopharma's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Sutro Biopharma shares in existence, roughly 80 shares are currently held short) or 0.0863% of the tradable shares (for every 100,000 tradable Sutro Biopharma shares, roughly 86 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Sutro Biopharma.

Find out more about how you can short Sutro Biopharma stock.

Sutro Biopharma share dividends

We're not expecting Sutro Biopharma to pay a dividend over the next 12 months.

Sutro Biopharma share price volatility

Over the last 12 months, Sutro Biopharma's shares have ranged in value from as little as $7.06 up to $28.3. A popular way to gauge a stock's volatility is its "beta".

STRO.US volatility(beta: 0.78)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sutro Biopharma's is 0.7847. This would suggest that Sutro Biopharma's shares are less volatile than average (for this exchange).

Sutro Biopharma overview

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site